JAHA:性别对心梗PCI术后患者死亡率的影响

2019-05-22 不详 MedSci原创

及时的冠脉介入治疗(PCI)可以降低心梗死亡风险,本研究的目的旨在评估性别差异对治疗时间和死亡风险的影响。本研究纳入了2013-2016年接受PCI治疗的13451名心梗患者(女性占22.5%),其中ST段抬高型心梗(STEMI)占47.8%,非ST段抬高型心梗(NSTEMI)占52.2%。在STEMI患者中,女性患者的治疗即时性弱于男性,30天死亡率也高于男性(9.3% vs 6.5%, P=0

及时的冠脉介入治疗(PCI)可以降低心梗死亡风险,本研究的目的旨在评估性别差异对治疗时间和死亡风险的影响。

本研究纳入了2013-2016年接受PCI治疗的13451名心梗患者(女性占22.5%),其中ST段抬高型心梗(STEMI)占47.8%,非ST段抬高型心梗(NSTEMI)占52.2%。在STEMI患者中,女性患者的治疗即时性弱于男性,30天死亡率也高于男性(9.3% vs 6.5%, P=0.005),经调整后的女性STD时间和DTB时间比男性分别多28.8和7.7min。在NSTEMI患者中,女性在治疗的即时性上与男性无明显差异。女性在STEMI患者中是更高30天死亡风险的预测因子,而在NSTEMI患者中无明显差异。

研究结果显示,在ST段抬高型心梗患者中,女性的治疗即时性更差,30天死亡率更高。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=373804, encodeId=9ef23e38047f, content=很好,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/22/c26524b0b4ca80000d38f0294262c002.jpg, createdBy=3cf52015303, createdName=苏小雨, createdTime=Sat Oct 12 11:24:11 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633846, encodeId=222c163384628, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sat Sep 28 15:13:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983624, encodeId=04e21983624b3, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Feb 12 23:13:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268147, encodeId=1aff126814efd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 24 02:13:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486438, encodeId=62a314864383f, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Fri May 24 02:13:00 CST 2019, time=2019-05-24, status=1, ipAttribution=)]
    2019-10-12 苏小雨

    很好,学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=373804, encodeId=9ef23e38047f, content=很好,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/22/c26524b0b4ca80000d38f0294262c002.jpg, createdBy=3cf52015303, createdName=苏小雨, createdTime=Sat Oct 12 11:24:11 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633846, encodeId=222c163384628, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sat Sep 28 15:13:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983624, encodeId=04e21983624b3, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Feb 12 23:13:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268147, encodeId=1aff126814efd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 24 02:13:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486438, encodeId=62a314864383f, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Fri May 24 02:13:00 CST 2019, time=2019-05-24, status=1, ipAttribution=)]
    2019-09-28 zxl736
  3. [GetPortalCommentsPageByObjectIdResponse(id=373804, encodeId=9ef23e38047f, content=很好,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/22/c26524b0b4ca80000d38f0294262c002.jpg, createdBy=3cf52015303, createdName=苏小雨, createdTime=Sat Oct 12 11:24:11 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633846, encodeId=222c163384628, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sat Sep 28 15:13:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983624, encodeId=04e21983624b3, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Feb 12 23:13:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268147, encodeId=1aff126814efd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 24 02:13:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486438, encodeId=62a314864383f, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Fri May 24 02:13:00 CST 2019, time=2019-05-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=373804, encodeId=9ef23e38047f, content=很好,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/22/c26524b0b4ca80000d38f0294262c002.jpg, createdBy=3cf52015303, createdName=苏小雨, createdTime=Sat Oct 12 11:24:11 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633846, encodeId=222c163384628, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sat Sep 28 15:13:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983624, encodeId=04e21983624b3, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Feb 12 23:13:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268147, encodeId=1aff126814efd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 24 02:13:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486438, encodeId=62a314864383f, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Fri May 24 02:13:00 CST 2019, time=2019-05-24, status=1, ipAttribution=)]
    2019-05-24 zhaohui6731
  5. [GetPortalCommentsPageByObjectIdResponse(id=373804, encodeId=9ef23e38047f, content=很好,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/22/c26524b0b4ca80000d38f0294262c002.jpg, createdBy=3cf52015303, createdName=苏小雨, createdTime=Sat Oct 12 11:24:11 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633846, encodeId=222c163384628, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sat Sep 28 15:13:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983624, encodeId=04e21983624b3, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Feb 12 23:13:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268147, encodeId=1aff126814efd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri May 24 02:13:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486438, encodeId=62a314864383f, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Fri May 24 02:13:00 CST 2019, time=2019-05-24, status=1, ipAttribution=)]

相关资讯

JACC:二尖瓣手术后起搏器的植入会增加患者死亡风险

与单独的二尖瓣手术(MVS)相比,MVS伴房颤消融术后的永久性起搏器植入率(PPM)会更高。本研究的目的旨在评估PPM在MVS伴房颤消融术患者中的发生率及临床预后。本研究纳入了243名无PPM植入的房颤患者,随机分成MVS组(n=117)和MVS联合射频消融组(n=126),消融组又随机分为肺静脉分离组(PVI,n=62)和双向迷宫组(n=64),分析结果显示,有35名(14.4%)患者在术后第一

JACC:残余炎症可增加PCI术后患者不良心脑血管事件风险

目前,对于残余炎症风险(RIR)对接受冠脉介入治疗(PCI)且基线低密度脂蛋白胆固醇(LDL-C)≤70mg/dl患者的影响尚不清楚。本研究的目的旨在评估PCI术后高RIR的发生率和影响。本研究纳入了2009-2016年基线LDL-C≤70mg/dl并进行了高敏C反应蛋白(hsCRP)评估的PCI患者,高RIR定义为hsCRP >2 mg/l。患者根据RIR状态分为持续性低RIR组、RIR减

JACC:一种可预测10年心衰风险模型的开发

目前尚无心衰的一级预防策略,且缺少心衰的风险预测工具。本研究的目的旨在推导出发展为心衰的10年风险方程。本研究纳入了1985-2000年30-79岁的无心血管疾病的参与者作为合并队列(PC),随机分为两组进行推导和内部验证,并在2个另外的队列中对模型方程进行验证。最终共有11771名对象纳入PC,女性占58%,黑种人占22%,平均年龄52±12岁,有1339名患有心衰。心衰风险的预测模型中包括年龄

Stroke:房颤与脑形态学的关系

房颤于认知下降和痴呆有关,独立于临床发生的卒中。其确切的机制尚未被完全阐明,但是房颤患者可以合并亚临床脑梗死(subclinical cerebral infarctions,SCI)、脑微梗死、慢性脑低灌注、炎症,并且共享血管危险因素比如高血压和糖尿病。脑 MRI 研究发现了脑形态学改变和认识功能受损之间的关系。 基于社区人群研究发现,白质高信号(white mater hyperintensi

盘点:JACC五月第三期研究一览

1.一种可预测10年心衰风险模型的开发DOI: 10.101

JACC:家族性高胆固醇血症在年轻心梗患者中常见

在美国年轻时经历心肌梗死(MI)的成年人中,关于家族性高胆固醇血症(FH)的患病率和治疗的数据有限。本研究纳入了YOUNG-MI注册数据库中的首发MI年龄小于50岁的患者,家族性高胆固醇血症的诊断根据荷兰脂质诊所标准。最终,共纳入了1996名患者,平均年龄为45岁,女性占19%,54%患者有ST段抬高型心梗,有180名(9%)患者诊断为FH。89.4%的FH患者和89.9%的非FH患者出院时接受有